ProNAi Therapeutics, Inc., announced that it has signed a supply agreement with Polymun Scientific GmbH, an Austrian contract biopharmaceutical developer, to manufacture the company’s PNT2258 DNAi®-based cancer therapeutic.
Under the terms of the agreement, Polymun will use its cross-flow injector technology to manufacture ProNAi’s liposome-formulated lead drug candidate, which is currently in the final stages of preclinical toxicology testing. ProNAi intends to bring PNT2258 to IND submission later this year.
Dr. Richard D. Gill, President and CEO of ProNAi, said, “Polymun has proven, successful experience in manufacturing drug product for U.S. clinical trials, and we are very happy to be working with them as we advance PNT2258 into the clinic. ProNAi is confident that Polymun’s manufacturing processes and technology are state-of-the-art and up to the task of formulating our oncology drug candidate, which features our novel oligo delivery method for the safe and effective administration of nucleic acid-based therapies.”
Dr. Dietmar Katinger, Vice President of Business Development of Polymun, said, “Polymun is delighted to have the opportunity to work with ProNAi in making this innovative drug candidate. Among our specialties, our company has considerable experience in working with liposomal formulations, and we look forward to this fruitful collaboration to help realize the potential of treating patients with these promising therapeutic nucleotides.”